logo
LA clinics lose funding for transgender health care as Trump executive orders take hold

LA clinics lose funding for transgender health care as Trump executive orders take hold

A Los Angeles health clinic says it's losing federal funding as a result of President Donald Trump 's executive orders targeting transgender people.
St. John's Community Health, one of the largest free and reduced-cost providers in Los Angeles, reported that the Centers for Disease Control and Prevention on Friday terminated a $1.6 million grant that was supposed to support its transgender health and social services program.
St. John's is the first California health provider to publicly report service impacts as a result of the Trump administration's actions. According to a letter from the CDC, the grant was ended in order to comply with an executive order requiring federal agencies to only recognize two genders.
'At St. John's we believe everyone has a fundamental human right to health care. You can disagree with quote-on-quote gender ideology and how people may choose to live their lives, but that doesn't give you the right to strip away their access to health care,' said Jim Mangia, president and chief executive of St. John's Community Health.
The grant, which started in 2022, was funded through the CDC's HIV prevention program. It allowed St. John's to operate a program for transgender adults that included sexually transmitted infection and HIV testing, health education and connections to social services including housing, substance use treatment and food stamps, Mangia said. More than 500 people received services through the grant annually.
Last week, along with thousands of clinics across the country, St. John's experienced a brief suspension in its access to more than $18 million of federal funding as a result of a separate executive order and internal budget memo that attempted to broadly freeze federal aid.
Two separate judges have blocked that order temporarily, but those decisions don't apply to the executive order now preventing St. John's from accessing its grant money for transgender patients, Mangia said.
St. John's will not cut services and is prepared to sue over the continued withholding of federal money, he added.
'We believe these grants were allocated by Congress and are constitutionally protected. We will pursue every avenue available to us to keep these programs funded,' Mangia said.
Several of Trump's executive orders in the past two weeks have targeted transgender people, including attempts to bar them from military service and prevent schools from recognizing pronouns or when a student transitions.
Last week, Trump issued another executive order barring federal funding for transgender health services for minors, including hormone therapy and surgical procedures. The order specifically called out federal research grants given to hospitals and medical schools as well as Medicare and Medicaid funding.
In that order and others, Trump describes gender-affirming care as 'sterilizing,' 'mutilation' and 'maiming,' characterizations that are in direct opposition to clinical evidence supported by major medical organizations including the American Medical Association, American Academy of Pediatrics and the American College of Obstetricians and Gynecologists, all of which oppose government interference in doctor-patient decisions.
Already hospitals across the country are stopping gender-affirming services for young people, according to news reports, including major hospitals in New York, Denver and Washington, D.C., which Trump praised in a statement as his 'intended effect.'
Organizations across the state that provide health and social services to transgender people are worried about their funding, said Jorge Reyes Salinas, communications director for Equality California, the state's largest LGBTQ and civil right's advocacy group.
'These actions by the Trump administration could deny trans people the right to medically necessary care and put their housing and employment at risk — deepening pre-existing health and economic disparities and fueling further discrimination,' Salinas said in a statement.
At least 24 organizations in California have received federal funding over the past five years for transgender health programs or research, according to federal data on grants distributed by the CDC and National Institutes of Health.
California's LGBTQ groups and top Democratic officials were quick to condemn the moves last week and assure state residents that California laws protecting transgender rights and services remain in place.
'California families seeking gender affirming care, and the doctors and staff who provide it, are protected under state laws like the Transgender, Gender Diverse, and Intersex (TGI) Inclusive Care Act. The President's order does not change that,' Attorney General Rob Bonta said in a statement.
State law requires state-regulated insurers to cover medically necessary gender-affirming care, including mental health services. It provides license protections for doctors who treat transgender patients, and includes broad nondiscrimination protections.
Still, Trump's orders have sown confusion among providers who are hesitant to run afoul of the law or lose vital money.
'Some medical providers are starting to preemptively cancel appointments with transgender youth because they're afraid of losing their license or funding,' said Dannie Ceseña, director of the California LGBTQ Health & Human Services Network. 'I'm hearing it across the state from a variety of partners.'
Ceseña said any such cancellations are 'inconsistent with California law' and families should contact the attorney general's office if they experience them.
___
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

California resident tests positive for the plague. Officials blame Lake Tahoe flea
California resident tests positive for the plague. Officials blame Lake Tahoe flea

Los Angeles Times

time3 hours ago

  • Los Angeles Times

California resident tests positive for the plague. Officials blame Lake Tahoe flea

A South Lake Tahoe resident has tested positive for the plague — yes, the same pest-transmitted disease estimated to have killed 25 million Europeans in the Middle Ages. It is believed that the person contracted the rare and dangerous disease after being bitten by an infected flea while camping in the South Lake Tahoe area, according to El Dorado County health officials. The patient is currently under the care of a medical professional and recovering at home, health officials said. 'Plague is naturally present in many parts of California, including higher elevation areas of El Dorado County,' said Kyle Fliflet, El Dorado County's acting director of public health, in a statement. 'It's important that individuals take precautions for themselves and their pets when outdoors, especially while walking, hiking and or camping in areas where wild rodents are present.' Plague is a very serious disease but can be treated with easily available antibiotics, according to the U.S. Centers for Disease Control and Prevention. The sooner a patient is diagnosed and receives treatment, the greater their chances of making a full recovery, according to the CDC. The disease is caused by the bacterium Yersinia pestis and is most commonly spread to humans by bites from infected fleas, according to El Dorado County health officials. The disease can also be spread by infected-rodent bites or by exposure to infected dogs and cats. The disease is extremely uncommon and infects on average seven people in the U.S. per year, according to the CDC. Nevertheless, it must be taken seriously due to the high potential for death if left untreated. The last plague case reported in El Dorado County was in 2020 and was also believed to be transmitted in the South Lake Tahoe area, health officials said. Two California plague cases were reported in 2015, likely caused by bites from an infected flea or rodent in Yosemite National Park. All three patients received treatment and made a full recovery, health officials said. There were 45 ground squirrels or chipmunks recorded with evidence of exposure to plague bacterium in the Lake Tahoe Basin from 2021 to the present, according to the California Department of Public Health, which routinely monitors rodent populations for plague activity across the state. El Dorado County health officials urged residents and visitors to take steps to avoid exposure to rodents or ticks when exploring the wilderness around Lake Tahoe. Measures include wearing long pants tucked into boots, using a bug repellent with DEET, never feeding or touching rodents, refraining from camping near animal burrows or dead rodents, and leaving dogs at home when possible. More than 80% of plague cases in the U.S. have been in the bubonic form, where patients will develop swollen, painful lymph nodes called buboes, according to the CDC. This form of the disease typically results from an infected-flea bite, and symptoms such as buboes, fever, headache, chills and weakness develop within two to eight days, according to the CDC. In July, an Arizona resident died of the pneumonic form of the plague, which can develop when bacteria spreads to the lungs of a patient with untreated bubonic plague. This is the most serious form of the plague and can have an incubation period of just one day. It's also the only form of the plague that can spread from human to human. During the Middle Ages, infected rats were to blame for the black death in Europe in the 14th century. The last urban rat-infected plague outbreak in America took place in Los Angeles in 1924 and 1925, according to the CDC.

The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research

Yahoo

time3 hours ago

  • Yahoo

The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research

Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research

Yahoo

time4 hours ago

  • Yahoo

The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research

Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store